← Compound Library

ANP (1-28)

Natriuretic Peptide / Cardiac Hormone

Also known as: Atrial Natriuretic Peptide · Atriopeptin · Carperitide

The endogenous 28-amino-acid cardiac peptide that promotes natriuresis, vasodilation, & inhibition of the renin-angiotensin-aldosterone system. Used clinically in Japan for acute heart failure.

Typical Dose

0.025–0.2 mcg/kg/min IV infusion (Japan: acute heart failure)

Route

Intravenous infusion

Cycle

Acute (24–72 hours)

Half-life

~2–3 minutes

Storage

2–8°C.

ⓘ

Insights on this page are consolidated from peer-reviewed literature and aggregated research data. They do not constitute medical advice. Consult a qualified healthcare professional before use.

Overview

Atrial Natriuretic Peptide (ANP) is a 28-amino-acid cyclic peptide released by atrial cardiomyocytes in response to increased wall stretch from volume or pressure overload. It promotes renal sodium & water excretion (natriuresis/diuresis), vasodilation via cGMP, & inhibits renin, aldosterone, & vasopressin. Carperitide (synthetic ANP) is approved in Japan for acute heart failure.

Research Indications

Acute heart failure

Effective

Approved in Japan as Carperitide. Reduces preload, afterload, & promotes natriuresis in acute HF.

Side Effects & Safety

Common

  • Hypotension
  • Headache

Uncommon

  • Electrolyte disturbances

When to Stop

  • Symptomatic hypotension
  • Aortic stenosis or obstructive cardiomyopathy

How to Reconstitute

1

Commercial IV product for clinical use.

Dosing math: Clinical use only.

Quality Indicators

Good — use as normal

  • Per manufacturer

Discard immediately

  • Per manufacturer

Community Insights

Self-reported. Reflects user experience, not clinical outcomes.

Verify what you have

Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-QTOF-MS & HPLC analysis with a signed analytical report.

Submit a sample